<DOC>
	<DOCNO>NCT00691145</DOCNO>
	<brief_summary>The objective study assess efficacy safety 0.1 % 0.03 % Tacrolimus ointment 12 month adult moderate severe atopic dermatitis .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety 0.1 % 0.03 % Tacrolimus Ointment Administered Adults With Moderate Severe Atopic Dermatitis</brief_title>
	<detailed_description>The main phase 6 month duration , follow phase 12 month allow collection efficacy safety data period include season patient , account seasonal variability strongly affect atopic dermatitis course .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patient may male female ethnic group Patient without restricted legal competence , suffers moderate severe atopic dermatitis ( Rajka/Langeland score least 4.5 ) Patient know responsive topical steroid Patient capable understanding purpose risk trial give write Informed Consent Female patient childbearing potential must agree maintain adequate birth control practice trial period first four week end study Patient meet follow criterion : Topical corticosteroid Systemic corticosteroid ( treatment AD ) Systemic nonsteroidal immunosuppressant ( e.g . cyclosporine , methotrexate ) Other investigational drug Light Treatments ( UVA , UVB ) Patient take agrees take complete study period medication therapy prohibit protocol Patient genetic epidermal barrier defect Netherton 's syndrome generalise erythroderma Patient pregnant breastfeed Patient skin infection affect ( treat ) area Patient know hypersensitivity macrolides general , tacrolimus excipient ointment Patient simultaneously participate drug trial le 28 day pass end previous trial one Any form substance abuse ( include drug alcohol abuse ) , psychiatric disorder condition , opinion investigator , may invalidate communication investigator Patient know HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Atopic dermatitis</keyword>
	<keyword>Tacrolimus ointment</keyword>
</DOC>